RecruitMe

First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax-AXL-ADC) in patients with solid tumors

Study of HuMax-AXL-ADC in Patients with Sarcoma

Sponsor:	Genmab
Enrolling:	Male and Female Patients
IRB Number:	AAAR6353
U.S. Govt. ID:	NCT02988817
Contact:	Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu

Additional Study Information: The purpose of this study is to establish the safety profile of the study drug HuMax-AXL-ADC in a mixed population of patients with specified solid tumors. HuMax-AXL-ADC binds to a specific antigen called Axl, which is expressed on the tumor cells in the cancer types treated in this trial. When the trial drug binds to the antigen on the tumor cell, the anticancer agent is preferentially delivered to these cells. In this way, mainly malignant tumor cells will be destroyed.

This study is closed

Investigator

Brian Henick, MD

See all studies by this doctor

Do You Qualify?

Are you 18 years or older?	Yes	No
Have you been diagnosed with sarcoma?	Yes	No
Have you had fewer than 3 prior treatments for your cancer?	Yes	No
Have you progressed on your last treatment for your cancer?	Yes	No

Submit

Cancel

This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.

I AGREE